Literature DB >> 10623727

Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

K Sandres1, M Dubois, C Pasquier, J L Payen, L Alric, M Duffaut, J P Vinel, J P Pascal, J Puel, J Izopet.   

Abstract

Hepatitis C virus (HCV) populations persist in vivo as a mixture of heterogeneous viruses called quasispecies. The relationship between the genetic heterogeneity of these variants and their responses to antiviral treatment remains to be elucidated. We have studied 26 virus strains to determine the influence of hypervariable region 1 (HVR-1) of the HCV genome on the effectiveness of alpha interferon (IFN-alpha) therapy. Following PCR amplification, we cloned and sequenced HVR-1. Pretreatment serum samples from 13 individuals with chronic hepatitis C whose virus was subsequently eradicated by treatment were compared with samples from 13 nonresponders matched according to the major factors known to influence the response, i.e., sex, genotype, and pretreatment serum HCV RNA concentration. The degree of virus variation was assessed by analyzing 20 clones per sample and by calculating nucleotide sequence entropy (complexity) and genetic distances (diversity). Types of mutational changes were also determined by calculating nonsynonymous substitutions per nonsynonymous site (K(a)) and synonymous substitutions per synonymous site (K(s)). The paired-comparison analysis of the nucleotide sequence entropy and genetic distance showed no statistical differences between responders and nonresponders. By contrast, nonsynonymous substitutions were more frequent than synonymous substitutions (P </= 0.05) in responders, but there was no significant difference in nonresponders. Nonsynonymous substitutions tended to be more frequent than synonymous substitutions in women (P = 0.06) but not in men. Nucleotide entropy and genetic distances were significantly related to serum RNA concentration (P </= 0.01). Our findings suggest that after controlling for the major determinants of interferon response, neither complexity nor diversity of the HVR-1 region is associated per se with virus eradication. Because a higher proportion of nonsynonymous substitutions than synonymous substitutions was found only in responders, host anti-HCV-specific immune response rather than viral factors may be playing an important role in the interferon response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623727      PMCID: PMC111585          DOI: 10.1128/jvi.74.2.661-668.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C.

Authors:  K Chayama; A Tsubota; Y Arase; S Saitoh; K Ikeda; T Matsumoto; M Hashimoto; M Kobayashi; M Kanda; T Morinaga
Journal:  J Hepatol       Date:  1995-12       Impact factor: 25.083

Review 2.  The treatment of chronic viral hepatitis.

Authors:  J H Hoofnagle; A M di Bisceglie
Journal:  N Engl J Med       Date:  1997-01-30       Impact factor: 91.245

3.  Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a.

Authors:  K Yoshioka; T Aiyama; A Okumura; M Takayanagi; K Iwata; T Ishikawa; Y Nagai; S Kakumu
Journal:  J Infect Dis       Date:  1997-03       Impact factor: 5.226

4.  Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients.

Authors:  G Missale; E Cariani; V Lamonaca; A Ravaggi; A Rossini; R Bertoni; M Houghton; Y Matsuura; T Miyamura; F Fiaccadori; C Ferrari
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

5.  Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients.

Authors:  D R Gretch; S J Polyak; J J Wilson; R L Carithers; J D Perkins; L Corey
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Chronic viral hepatitis--benefits of current therapies.

Authors:  J H Hoofnagle; D Lau
Journal:  N Engl J Med       Date:  1996-05-30       Impact factor: 91.245

7.  A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures.

Authors:  Y K Shimizu; H Igarashi; T Kiyohara; T Cabezon; P Farci; R H Purcell; H Yoshikura
Journal:  Virology       Date:  1996-09-15       Impact factor: 3.616

8.  Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

Authors:  M Martinot-Peignoux; P Marcellin; M Pouteau; C Castelnau; N Boyer; M Poliquin; C Degott; I Descombes; V Le Breton; V Milotova
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

9.  Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.

Authors:  S M Wolinsky; B T Korber; A U Neumann; M Daniels; K J Kunstman; A J Whetsell; M R Furtado; Y Cao; D D Ho; J T Safrit
Journal:  Science       Date:  1996-04-26       Impact factor: 47.728

10.  Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients.

Authors:  H Khorsi; S Castelain; A Wyseur; J Izopet; V Canva; A Rombout; D Capron; J P Capron; F Lunel; L Stuyver; G Duverlie
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

View more
  21 in total

1.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

Review 2.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.

Authors:  Vicki M Park; Barbara C Mason; Julia Krushkal; Rongling Li; Caroline Riely; Jaquelyn Fleckenstein
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

4.  Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C.

Authors:  Jian Wang; Gui-Ju Xiang; Bing-Xiang Liu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

5.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.

Authors:  Patrizia Farci; Rita Strazzera; Harvey J Alter; Stefania Farci; Daniela Degioannis; Alessandra Coiana; Giovanna Peddis; Francesco Usai; Giancarlo Serra; Luchino Chessa; Giacomo Diaz; Angelo Balestrieri; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

6.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  New natural intergenotypic (2/5) recombinant of hepatitis C virus.

Authors:  Florence Legrand-Abravanel; Julie Claudinon; Florence Nicot; Martine Dubois; Sabine Chapuy-Regaud; Karine Sandres-Saune; Christophe Pasquier; Jacques Izopet
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

8.  Plasma and liver hepatitis C virus variability in patients coinfected with human immunodeficiency virus.

Authors:  Anne-Christine Jouvencel; Didier Neau; Muriel Faure; Martine Neau; Christophe Martinaud; Elisabeth Legrand; Pascale Trimoulet; Isabelle Garrigue; Brigitte Le Bail; Paulette Bioulac-Sage; Michel Dupon; Jean-Marie Ragnaud; Herve Fleury; Marie-Edith Lafon
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

9.  Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.

Authors:  Ana Maria Contreras; Yoichi Hiasa; Wenping He; Adam Terella; Emmett V Schmidt; Raymond T Chung
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.

Authors:  Xiaofeng Fan; Qing Mao; Donghui Zhou; Yang Lu; Jianwei Xing; Yanjuan Xu; Stuart C Ray; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.